sofosbuvir/ledipasvir方案治疗HCV 6a型慢性丙型肝炎的临床效果和安全性

李威; 康谊; 丁岗强; 尚佳; 周元平

doi:10.3969/j.issn.1001-5256.2019.03.015

sofosbuvir/ledipasvir方案治疗HCV 6a型慢性丙型肝炎的临床效果和安全性

DOI: 10.3969/j.issn.1001-5256.2019.03.015

1. 河南省人民医院感染科
2. 南方医科大学南方医院感染内科

基金项目:

国家自然科学基金资助项目(81470856)；河南省科技攻关计划项目(162102310030)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 1541
- HTML全文浏览量: 11
- PDF下载量: 913
- 被引次数: 0
出版历程
- 收稿日期: 2018-11-30
- 出版日期: 2019-03-20

Clinical effect and safety of sofosbuvir-ledipasvir regimen in treatment of patients with HCV genotype 6a chronic hepatitis C

Department of Infectious Diseases, Henan Provincial People's Hospital

Research funding:

摘要

摘要: 目的探讨sofosbuvir/ledipasvir（SOF+LDV）治疗HCV 6a型慢性丙型肝炎的效果和安全性。方法本研究为前瞻性观察研究,纳入2014年10月到2016年12月在河南省人民医院及南方医院感染科就诊的63例HCV 6a型慢性丙型肝炎患者。将所纳入患者分为2组,分别给予SOF+LDV 12周、PEG-IFN联合利巴韦林（PR） 24周抗病毒治疗。在治疗期间及治疗终止后随访检测HCV RNA,评价病毒学应答。计数资料2组间比较采用χ2检验;计量资料2组间比较采用Mann-Whitney U检验。结果 PR组和SOF+LDV组患者的快速病毒学应答率（85. 3%vs 100%）、治疗结束时病毒学应答率（94. 1%vs 100%）差异均无统计学意义（P值均> 0. 05）。SOF+LDV组持续病毒学应答率为96. 4%,显著高于PR组的73. 5%（χ2=4. 38,P=0. 036）。PR组总体不良反应发生率明显高于SOF+LDV组（χ2=7. 54,P=0. 006）。SOF+LDV组后续随访有1例肝硬化患者发生小肝癌。而PR组至随访截止时间无1例患者发生肝癌。结...
- 肝炎,丙型,慢性 /
- 基因型 /
- 持续病毒学应答 /
- 治疗结果
Abstract: Objective To investigate the clinical effect and safety of sofosbuvir ( SOF) -ledipasvir ( LDV) in the treatment of patients withHCV genotype 6 a chronic hepatitis C ( CHC) . Methods A total of 63 patients with HCV genotype 6 a CHC who visited Department of In-fectious Diseases, Henan Provincial People's Hospital and Nanfang Hospital, from October 2014 to December 2016 were enrolled in thisprospective observational study. They were divided into SOF-LDV group ( treated with SOF-LDV for 12 weeks) and PR group ( treatedwith pegylated interferon combined with ribavirin for 24 weeks) . HCV RNA was measured during treatment and follow-up, and virologicresponse was evaluated. The chi-square test was used for comparison of categorical data between two groups, and the Mann-Whitney Utest was used for comparison of continuous data between two groups. Results There were no significant differences between the PR groupand the SOF-LDV group in rapid virologic response rate ( 85. 3% vs 100%, P > 0. 05) and virologic response rate at the end of treatment ( 94. 1% vs 100%, P > 0. 05) . The SOF-LDV group had a significantly higher sustained virologic response rate than the PR group ( 96.4% vs 73. 5%, χ2= 4. 38, P = 0. 036) . The PR group had a significantly higher incidence rate of adverse events than the SOF-LDV group ( χ2= 7. 54, P = 0. 006) . During follow-up, one patient with liver cirrhosis in the SOF-LDV group developed small hepatocellular carcino-ma, while no patient in the PR group developed liver cancer at the end of follow-up. Conclusion SOF-LDV for 12 weeks is safe and ef-fective in the treatment of HCV genotype 6 a CHC, but liver cancer should be closely monitored in patients with liver cirrhosis.
- hepatitis C, chronic /
- genotype /
- sustained virological response /
- treatment outcome

HTML全文

参考文献(16)

[1] CONTI F, BUONFIGLIOLI F, SCUTERI A, et al. Early occur-rence and recurrence of hepatocellular carcinoma in HCV-re-lated cirrhosis treated with direct-acting antivirals[J]. J Hep-atol, 2016, 65 (4) :727-733.

[2] NAGATA H, NAKAGAWA M, ASAHINA Y, et al. Effect of in-terferon-based and-free therapy on early occurrence andrecurrence of hepatocellular carcinoma in chronic hepatitis C[J]. J Hepatol, 2017, 67 (5) :933-939.

[3] ZENG QL, XU GH, ZHANG JY, et al. Generic ledipasvir-so-fosbuvir for patients with chronic hepatitis C:A real-life ob-servational study[J]. J Hepatol, 2017, 66 (6) :1123-1129.

[4] Chinese Society of Hepatology and Chinese Society of Infec-tious Diseases, Chinese Medical Association. The guideline ofprevention and treatment for hepatitis C:A 2015 update[J]. JCIin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[5] LI W, NING HB, KANG Y, et al. Impact of directly sequencedcore and non-structrural protein 5B regions on hepatitis C vi-rus genotyping[J]. Chin J Infect Dis, 2015, 33 (6) :343-345. (in Chinese) 李威, 宁会彬, 康谊, 等.核心蛋白和非结构蛋白5B直接测序法对丙型肝炎病毒基因分型的影响[J].中华传染病杂志, 2015, 33 (6) :343-345.

[6] LI W, ZENG Y, WANG J, et al. Predicting sustained viral re-sponse to hepatitis C using a rapid and simple IL28Brs8099917 genotyping assay[J]. Antiviral Res, 2012, 94 (1) :54-56.

[7] SETO WK, LAI CL, FUNG J, et al. Natural history of chronichepatitis C:Genotype 1 versus genotype 6[J]. J Hepatol, 2010, 53 (3) :444-448.

[8] LU L, NAKANO T, HE Y, et al. Hepatitis C virus genotype dis-tribution in China:Predominance of closely related subtype 1bisolates and existence of new genotype 6 variants[J]. J MedVirol, 2005, 75 (4) :538-549.

[9] WEI JF, ZHANG TS, HUANG HH, et al. A novel method forhepatitis C virus genotyping using RT-PCR reverse dot blothybridizationte chnique[J]. J South Med Univ, 2010, 30 (10) :2270-2272, 2276. (in Chinese) 魏君锋, 张太松, 黄辉红, 等.反向点杂交法检测广东地区丙型肝炎病毒基因型和基因亚型[J].南方医科大学学报, 2010, 30 (10) :2270-2272, 2276.

[10] ZHOU Y, WANG X, MAO Q, et al. Changes in modes of hep-atitis C infection acquisition and genotypes in southwest China[J]. J Clin Virol, 2009, 46 (3) :230-233.

[11] RAO H, WEI L, LOPEZ-TALAVERA JC, et al. Distributionand clinical correlates of viral and host genotypes in Chinesepatients with chronic hepatitis C virus infection[J]. J Gastro-enterol Hepatol, 2015, 29 (3) :545-553.

[12] CUI WG, XUE XJ, LIU CH, et al. Epidemiological survey onthe hepatitis C virus and its genotyping analysis in Henan prov-ince in 2012[J]. Clin J Prev Med, 2013, 47 (6) :518-522. (in Chinese) 崔为国, 薛秀娟, 刘春华, 等. 2012年河南省丙型肝炎病毒感染状况及基因型分布调查[J].中华预防医学杂志, 2013, 47 (6) :518-522.

[13] LI W, XI L, CAI Q, et al. Changes in the distribution of hepati-tis C virus genotypes and their association with shifts in trans-mission routes in Henan, China[J]. J Public Health, 2018, 26 (2) :157-162.

[14] ESTEBAN JI, SAULEDA S, QUER J. The changing epidemiol-ogy of hepatitis C virus infection in Europe[J]. J Hepatol, 2008, 48 (1) :148-162.

[15] ZHOU YQ, WANG XH, HONG GH, et al. Twenty-four weeksof pegylated interferon plus ribavirin effectively treat patientswith HCV genotype 6a[J]. J Viral Hepat, 2011, 18 (8) :595-600.

[16] WANG Q, LUO BF, WEl L. A risk assessment of disease pro-gression after virus elimination with ch ronic hepatitis C[J]. JClin Hepatol, 2018, 34 (2) :227-228. (in Chinese) 王琴, 罗碧芬, 魏来.慢性丙型肝炎清除病毒后疾病进展风险评估[J].临床肝胆病杂志, 2018, 34 (2) :227-228.

施引文献

资源附件(0)

访问统计